Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Cited by (6,138)

Items 101–200 of 6,138

1. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
   American Diabetes Association Professional Practice Committee · 2022 · Diabetes Care
2. Molecular pathways that drive diabetic kidney disease
   Samer Mohandes, Tomohito Doke, Hailong Hu, Dhanunjay Mukhi, Poonam Dhillon, Katalin Suszták · 2023 · Journal of Clinical Investigation
3. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
   American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Das, Sandeep R., Echouffo-Tcheugui, Justin B. et al. · 2025 · Diabetes Care
4. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
   Sacks, David B., Arnold, Mark, Bakris, George L., Bruns, David E., Horvath, Andrea R., Lernmark, Åke, Metzger, Boyd E., Nathan, David M., Kirkman, M. Sue · 2023 · Diabetes Care
5. Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease
   Sunil Bhandari, Samir P. Mehta, Arif Khwaja, John G.F. Cleland, Natalie J. Ives, Elizabeth A. Brettell, Marie Chadburn, Paul Cockwell · 2022 · New England Journal of Medicine
6. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
   Maddox, Thomas M., Januzzi, James L., Allen, Larry A., Breathett, Khadijah, Brouse, Sara, Butler, Javed, Davis, Leslie L., Fonarow, Gregg C., Ibrahim, Nasrien E., Lindenfeld, JoAnn et al. · 2024 · Journal of the American College of Cardiology
7. 2023 ESC Guidelines for the management of acute coronary syndromes
   Robert A. Byrne, Xavier Rosselló, John Joseph Coughlan, Emanuele Barbato, Colin Berry, Alaide Chieffo, Marc J. Claeys, Gheorghe‐Andrei Dan, Marc Richard Dweck, Mary Galbraith et al. · 2023 · European Heart Journal Acute Cardiovascular Care
8. Long-term outcomes of acute kidney injury and strategies for improved care
   Matthew Thomas James, Meha Bhatt, Neesh Pannu, Marcello A. Tonelli · 2020 · Nature Reviews Nephrology
9. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives
   Marc Evans, Ruth D. Lewis, Angharad R. Morgan, Martin Whyte, Wasim Hanif, Stephen Charles Bain, Sarah Davies, Umesh Kumar Dashora, Zaheer R Yousef, Dipesh Patel et al. · 2021 · Advances in Therapy
10. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
    Jhund, Pardeep S., Solomon, Scott D., Docherty, Kieran F., Heerspink, Hiddo J.L., Anand, Inder S., Böhm, Michael, Chopra, Vijay, de Boer, Rudolf A., Desai, Akshay S., Ge, Junbo et al. · 2021 · Circulation
11. Atherosclerosis in Chronic Kidney Disease
    José Manuel Valdivielso, Diego Rodrı́guez-Puyol, Julio Pascual, Clara Barrios, Marcelino Bermúdez-López, María Dolores Sánchez-Niño, María Pérez-Fernández, Alberto Ortíz · 2019 · Arteriosclerosis Thrombosis and Vascular Biology
12. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
    Heerspink, Hiddo J L, Sattar, Naveed, Pavo, Imre, Haupt, Axel, Duffin, Kevin L, Yang, Zhengyu, Wiese, Russell J, Tuttle, Katherine R, Cherney, David Z I · 2022 · The Lancet Diabetes & Endocrinology
13. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
    Arnold, Suzanne V., Bhatt, Deepak L., Barsness, Gregory W., Beatty, Alexis L., Deedwania, Prakash C., Inzucchi, Silvio E., Kosiborod, Mikhail, Leiter, Lawrence A., Lipska, Kasia J., Newman, Jonathan D. et al. · 2020 · Circulation
14. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
    Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai, Yoshio Fujioka, Yasushi Ishigaki, Shinji Koba, Hirotoshi Ohmura, Tetsuo Shoji, Koutaro Yokote, Hiroshi Yoshida et al. · 2023 · Journal of Atherosclerosis and Thrombosis
15. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Yun, Jae-Seung, Ko, Seung-Hyun · 2021 · Metabolism
16. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
    Tentolouris, Anastasios, Vlachakis, Panayotis, Tzeravini, Evangelia, Eleftheriadou, Ioanna, Tentolouris, Nikolaos · 2019 · International Journal of Environmental Research and Public Health
17. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score
    Matthew W. Segar, Muthiah Vaduganathan, Kershaw V. Patel, Darren K. McGuire, Javed Butler, Gregg C. Fonarow, Mujeeb A. Basit, Vaishnavi Kannan, Justin Lee Grodin, Brendan M. Everett et al. · 2019 · Diabetes Care
18. Diabetes mellitus—Progress and opportunities in the evolving epidemic
    E. Dale Abel, Anna L. Gloyn, Carmella Evans‐Molina, Joshua J. Joseph, Shivani Misra, Utpal B. Pajvani, Judith Simcox, Katalin Suszták, Daniel J. Drucker · 2024 · Cell
19. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial
    Mahaffey, Kenneth W., Jardine, Meg J., Bompoint, Severine, Cannon, Christopher P., Neal, Bruce, Heerspink, Hiddo J.L., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George et al. · 2019 · Circulation
20. KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease
    Yutaro Mori, Amrendra K. Ajay, Jae‐Hyung Chang, Shan Mou, Huiping Zhao, Seiji Kishi, Jiahua Li, Craig R. Brooks, Sheng Xiao, Heung‐Myong Woo et al. · 2021 · Cell Metabolism
21. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
    Sandra Naaman, George L. Bakris · 2023 · Diabetes Care
22. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
    Brendon Lange Neuen, Megumi Oshima, Rajiv Agarwal, Clare Gabrielle Arnott, David Z.I. Cherney, Robert Edwards, Anna Maria Langkilde, Kenneth W. Mahaffey, Darren K. McGuire, Bruce Neal et al. · 2022 · Circulation
23. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
    Heerspink, Hiddo J L, Karasik, Avraham, Thuresson, Marcus, Melzer-Cohen, Cheli, Chodick, Gabriel, Khunti, Kamlesh, Wilding, John P H, Garcia Rodriguez, Luis Alberto, Cea-Soriano, Lucia, Kohsaka, Shun et al. · 2020 · The Lancet Diabetes & Endocrinology
24. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
    Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana M. Isaacs, Eric L. Johnson et al. · 2022 · Diabetes Care
25. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
    de Boer, Ian H., Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A. et al. · 2020 · Kidney International
26. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
    Cherney, David Z I, Dekkers, Claire C J, Barbour, Sean J, Cattran, Daniel, Abdul Gafor, Abdul Halim, Greasley, Peter J, Laverman, Gozewijn D, Lim, Soo Kun, Di Tanna, Gian Luca, Reich, Heather N et al. · 2020 · The Lancet Diabetes & Endocrinology
27. Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications
    Dongrong Yang, Meng‐Yan Wang, Chenglin Zhang, Yu Wang · 2024 · Frontiers in Endocrinology
28. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease
    Gornik, Heather L., Aronow, Herbert D., Goodney, Philip P., Arya, Shipra, Brewster, Luke Packard, Byrd, Lori, Chandra, Venita, Drachman, Douglas E., Eaves, Jennifer M., Ehrman, Jonathan K. et al. · 2024 · Journal of the American College of Cardiology
29. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure
    Michael E. Nassif, Mohammed Qintar, Sheryl L. Windsor, Rita A. Jermyn, David M. Shavelle, Fengming Tang, Sumant Lamba, Kunjan A. Bhatt, John E. Brush, Andrew B. Civitello et al. · 2021 · Circulation
30. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
    Faiez M. Zannad, João Pedro Ferreira, Stuart Pocock, Cordula Zeller, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Sibylle Jenny Hauske, Martina Brueckmann, Egon Pfarr et al. · 2020 · Circulation
31. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
    Jorge Ignacio Fonseca-Correa, Ricardo Correa‐Rotter · 2021 · Frontiers in Medicine
32. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
    Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay et al. · 2023 · Diabetes Care
33. Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
    André Jacques Scheen · 2020 · Nature Reviews Endocrinology
34. Carbohydrate-based drugs launched during 2000−2021
    Xin Cao, Xiaojing Du, Heng Jiao, Quanlin An, Ruoxue Chen, Pengfei Fang, Jing Wang, Biao Yu · 2022 · Acta Pharmaceutica Sinica B
35. Gliflozins in the Management of Cardiovascular Disease
    Eugene Braunwald · 2022 · New England Journal of Medicine
36. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Echouffo-Tcheugui, Justin B., Ekhlaspour, Laya et al. · 2025 · Diabetes Care
37. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function
    Eoin Patrick Brennan, Phillip Kantharidis, Mark E. Cooper, Catherine Godson · 2021 · Nature Reviews Nephrology
38. Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease
    Chan‐Young Jung, Tae‐Hyun Yoo · 2022 · Diabetes & Metabolism Journal
39. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
    Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, Luca Rinaldi, Anna Di Martino, Gaetana Albanese, Jessica Di Salvo, Raffaella Epifani, Raffaele Marfella, Giovanni Docimo et al. · 2022 · International Journal of Molecular Sciences
40. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
    Shaman, Ahmed M., Bain, Stephen C., Bakris, George L., Buse, John B., Idorn, Thomas, Mahaffey, Kenneth W., Mann, Johannes F.E., Nauck, Michael A., Rasmussen, Søren, Rossing, Peter et al. · 2022 · Circulation
41. Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
    Arnott, Clare, Li, Qiang, Kang, Amy, Neuen, Brendon L., Bompoint, Severine, Lam, Carolyn S. P., Rodgers, Anthony, Mahaffey, Kenneth W., Cannon, Christopher P., Perkovic, Vlado et al. · 2020 · Journal of the American Heart Association
42. Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
    Jonatan Barrera‐Chimal, Ixchel Lima‐Posada, George L. Bakris, Frédéric Jaisser · 2021 · Nature Reviews Nephrology
43. Nitric oxide signalling in kidney regulation and cardiometabolic health
    Mattias Carlström · 2021 · Nature Reviews Nephrology
44. Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies
    Jin, Qiao, Ma, Ronald Ching Wan · 2021 · Cells
45. Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial
    Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Waheed Jamal, Afshin Salsali, Janet M. Schnee, Karen A. Kimura, Cordula Zeller, Jyothis Thomas George, Martina Brueckmann et al. · 2019 · European Journal of Heart Failure
46. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
    Rossing, Peter, Baeres, Florian M M, Bakris, George, Bosch-Traberg, Heidrun, Gislum, Mette, Gough, Stephen C L, Idorn, Thomas, Lawson, Jack, Mahaffey, Kenneth W, Mann, Johannes F E et al. · 2023 · Nephrology Dialysis Transplantation
47. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial
    Kosiborod, Mikhail N, Esterline, Russell, Furtado, Remo H M, Oscarsson, Jan, Gasparyan, Samvel B, Koch, Gary G, Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay et al. · 2021 · The Lancet Diabetes & Endocrinology
48. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
    Clifford J. Bailey, Caroline Day, Srikanth Bellary · 2022 · Current Diabetes Reports
49. Inflammatory Targets in Diabetic Nephropathy
    Javier Donate‐Correa, Desirée Luis-Rodríguez, Ernesto Martín‐Núñez, Víctor G. Tagua, Carolina Hernández-Carballo, Carla María Ferri, Ana Elena Rodríguez‐Rodríguez, Carmen Mora Fernández, Juan F. Navarro‐González · 2020 · Journal of Clinical Medicine
50. Pharmacological treatment of hyperglycemia in type 2 diabetes
    Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees · 2021 · Journal of Clinical Investigation
51. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
    Annabelle M Warren, Søren Tang Knudsen, Mark E. Cooper · 2019 · Expert Opinion on Therapeutic Targets
52. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules
    Jinpeng Li, Haijie Liu, Susumu Takagi, Kyoko Nitta, Munehiro Kitada, Swayam Prakash Srivastava, Yuta Takagaki, Keizo Kanasaki, Daisuke Koya · 2020 · JCI Insight
53. Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies
    Hao Wu, Romer A. González-Villalobos, Xiang Yao, Dermot F. Reilly, Tao Chen, Matthew M. Rankin, Eugene Myshkin, Matthew Douglas Breyer, Benjamin D. Humphreys · 2022 · Cell Metabolism
54. Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
    Cosentino, Francesco, Cannon, Christopher P., Cherney, David Z.I., Masiukiewicz, Urszula, Pratley, Richard, Dagogo-Jack, Sam, Frederich, Robert, Charbonnel, Bernard, Mancuso, James, Shih, Weichung J. et al. · 2020 · Circulation
55. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
    Calvin Ke, K.M. Venkat Narayan, Juliana C.N. Chan, Prabhat Jha, Baiju R. Shah · 2022 · Nature Reviews Endocrinology
56. Treatment of Diabetic Kidney Disease: Current and Future
    Tomotaka Yamazaki, Imari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku · 2021 · Diabetes & Metabolism Journal
57. Mechanisms of podocyte injury and implications for diabetic nephropathy
    Federica Barutta, Stefania Bellini, Gabriella Gruden · 2022 · Clinical Science
58. Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
    Matoba, Keiichiro, Takeda, Yusuke, Nagai, Yosuke, Kawanami, Daiji, Utsunomiya, Kazunori, Nishimura, Rimei · 2019 · International Journal of Molecular Sciences
59. SGLT2i: beyond the glucose-lowering effect
    Lihua Ni, Cheng Yuan, Guopeng Chen, Changjiang Zhang, Xiaoyan Wu · 2020 · Cardiovascular Diabetology
60. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
    Sargeant, Jack Alistair, Henson, Joseph, King, James Adam, Yates, Thomas, Khunti, Kamlesh, Davies, Melanie Jane · 2019 · Endocrinology and Metabolism
61. Protective Factors and the Pathogenesis of Complications in Diabetes
    Marc Gregory Yu, Daniel Gordin, Jialin Fu, Kyoungmin Park, Qian Li, George Liang King · 2023 · Endocrine Reviews
62. Diabetic kidney diseases revisited: A new perspective for a new era
    Haiyan Fu, Silvia Liu, Sheldon Bastacky, Xiaojie Wang, Xiao‐Jun Tian, Dong Feng Zhou · 2019 · Molecular Metabolism
63. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
    Iris E. Beldhuis, Carolyn S.P. Lam, Jeffrey M. Testani, Adriaan A. Voors, Harriette G.C. Van Spall, Jozine M. ter Maaten, Kevin Damman · 2022 · Circulation
64. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
    Birkeland, Kåre I., Bodegard, Johan, Eriksson, Jan W., Norhammar, Anna, Haller, Hermann, Linssen, Gerard C.M., Banerjee, Amitava, Thuresson, Marcus, Okami, Suguru, Garal‐Pantaler, Elena et al. · 2020 · Diabetes, Obesity and Metabolism
65. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
    Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, David Z.I. Cherney · 2022 · Kidney International Reports
66. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
    Niels Jongs, Tom Greene, Glenn Matthew Chertow, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa‐Rotter, Peter R Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto et al. · 2021 · The Lancet Diabetes & Endocrinology
67. Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease
    Na Wang, Chun Zhang · 2024 · Antioxidants
68. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
    Hiddo J.L. Heerspink, Bergur V. Stefánsson, Glenn Matthew Chertow, Ricardo Correa‐Rotter, Tom Greene, Fan Fan Hou, Magnus Lindberg, John J.V. McMurray, Peter R Rossing, Robert D. Toto et al. · 2019 · Nephrology Dialysis Transplantation
69. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants
    Ogo I. Egbuna, Brandon Zimmerman, George Manos, Anne Fortier, Madalina Chirieac, Leslie A. Dakin, David J. Friedman, Kate Bramham, Kirk Nicholas Campbell, Bertrand Knebelmann et al. · 2023 · New England Journal of Medicine
70. Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism
    Yi Fu, Yu Sun, Mei Wang, Yunfeng Hou, Wei Chieh Huang, Di Zhou, Ziying Wang, Shuting Yang, Wei Tang, Junhui Zhen et al. · 2020 · Cell Metabolism
71. 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
    Mee Kyoung Kim, Seung‐Hyun Ko, Bo‐Yeon Kim, Eun Seok Kang, Junghyun Noh, Soo‐Kyung Kim, Seok-O Park, Kyu Yeon Hur, Suk Chon, Min Kyong Moon et al. · 2019 · Diabetes & Metabolism Journal
72. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
    Peter R Rossing, Stefan D. Anker, Gerasimos S Filippatos, Bertram Pitt, Luis Miguel Ruilope, Andreas L. Birkenfeld, Janet B. McGill, Sylvia E. Rosas, Amer Joseph, Martin Gebel et al. · 2022 · Diabetes Care
73. Cardiovascular disease in diabetes, beyond glucose
    Robert H. Eckel, Karin Bornfeldt, Ira J. Goldberg · 2021 · Cell Metabolism
74. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
    Luis Miguel Ruilope, Rajiv Agarwal, Stefan D. Anker, George L. Bakris, Gerasimos Filippatos, Christina Nowack, Peter Kolkhof, Amer Joseph, Nicole Mentenich, Bertram Pitt et al. · 2019 · American Journal of Nephrology
75. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics
    Milton Packer · 2020 · American Journal of Kidney Diseases
76. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials
    Gilson Costa Fernandes, Amanda Dantas Ferreira Fernandes, Rhanderson N. Cardoso, Jorge Peñalver, Leonardo Knijnik, Raul David Mitrani, Robert J. Myerburg, Jeffrey J. Goldberger · 2021 · Heart Rhythm
77. Glomerular hyperfiltration
    Cortinovis, Monica, Perico, Norberto, Ruggenenti, Piero, Remuzzi, Andrea, Remuzzi, Giuseppe · 2022 · Nature Reviews Nephrology
78. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
    Kraus, Bettina J., Weir, Matthew R., Bakris, George L., Mattheus, Michaela, Cherney, David Z.I., Sattar, Naveed, Heerspink, Hiddo J.L., Ritter, Ivana, von Eynatten, Maximilian, Zinman, Bernard et al. · 2021 · Kidney International
79. Insights into Glomerular Filtration and Albuminuria
    Thomas R. Benzing, David J. Salant · 2021 · New England Journal of Medicine
80. Hypertension management in patients with cardiovascular comorbidities
    Lucas Lauder, Felix Mahfoud, Michel Azizi, Deepak L. Bhatt, Sebastian Ewen, Kazuomi Kario, Gianfranco Parati, Patrick Rossignol, Markus Peter Schlaich, Koon Kang Teo et al. · 2022 · European Heart Journal
81. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
    Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Mandeep Singh Bajaj, Kirthikaa Balapattabi, Elizabeth Ann Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Kenneth J. Cusi, Justin Basile Echouffo-Tcheugui et al. · 2024 · Diabetes Care
82. 9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
    American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
83. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure
    Ravi B. Patel, Gregg C. Fonarow, Stephen John Greene, Shuaiqi Zhang, Brooke Alhanti, Adam D. DeVore, Javed Butler, Paul A. Heidenreich, Joanna Huang, Michelle Maya Kittleson et al. · 2021 · Journal of the American College of Cardiology
84. Effects of dapagliflozin in stage 4 chronic kidney disease
    Chertow, Glenn M., Vart, Priya, Jongs, Niels, Toto, Robert D., Gorriz, Jose Luis, Hou, Fan Fan, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David et al. · 2021 · Journal of the American Society of Nephrology
85. Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
    Stefan D. Anker, Muhammad Usman, Markus S. Anker, Javed Butler, Michael Böhm, William T. Abraham, Marianna Adamo, Vijay Chopra, Mariantonietta Cicoira, Francesco Cosentino et al. · 2023 · European Journal of Heart Failure
86. Diabetic Kidney Disease: Challenges, Advances, and Opportunities
    Ya Chen, Kyung Lee, Zhaohui Ni, Cijiang He · 2020 · Kidney Diseases
87. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
    Hesp, Anne C., Schaub, Jennifer A., Prasad, Pottumarthi V., Vallon, Volker, Laverman, Gozewijn D., Bjornstad, Petter, van Raalte, Daniël H. · 2020 · Kidney International
88. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis
    Siddharth M. Patel, Yu Mi Kang, KyungAh Im, Brendon Lange Neuen, Stefan D. Anker, Deepak L. Bhatt, Javed Butler, David Z.I. Cherney, Brian Lee Claggett, Robert A. Fletcher et al. · 2024 · Circulation
89. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association
    Rangaswami, Janani, Bhalla, Vivek, de Boer, Ian H., Staruschenko, Alexander, Sharp, Johanna A., Singh, Radhika Rajgopal, Lo, Kevin Bryan, Tuttle, Katherine, Vaduganathan, Muthiah, Ventura, Hector et al. · 2020 · Circulation
90. The Interplay Between Bone and Glucose Metabolism
    Cristiana Cipriani, Luciano Colangelo, Rachele Santori, Mario Renella, Monia Mastrantonio, Salvatore Minisola, Jessica Pepe · 2020 · Frontiers in Endocrinology
91. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
    David Collins. Wheeler, Bergur V. Stefánsson, М. М. Батюшин, Oleksandr V. Bilchenko, David Z.I. Cherney, Glenn Matthew Chertow, Walter Douthat, Jamie P. Dwyer, Elizabeth Escudero, Roberto Pecoits‐Filho et al. · 2020 · Nephrology Dialysis Transplantation
92. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
    Alicic, Radica Z., Cox, Emily J., Neumiller, Joshua J., Tuttle, Katherine R. · 2021 · Nature Reviews Nephrology
93. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
    Mann, Johannes F. E., Rossing, Peter, Bakris, George, Belmar, Nicolas, Bosch-Traberg, Heidrun, Busch, Robert, Charytan, David M., Hadjadj, Samy, Gillard, Pieter, Górriz, José Luis et al. · 2024 · Nature Medicine
94. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
    Devinder Singh Dhindsa, Pratik B. Sandesara, Michael David Shapiro, Nathan D. Wong · 2020 · Frontiers in Cardiovascular Medicine
95. Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies
    Carlo Alberto Ricciardi, Luigi Gnudi · 2021 · Metabolism
96. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
    Bo Xu, Shaoqian Li, Bo Kang, Jiecan Zhou · 2022 · Cardiovascular Diabetology
97. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
    Hang‐Long Li, Gregory Y.H. Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-zhen Wu, Qing-Wen Ren, Hung‐Fat Tse, Bernard M.Y. Cheung, Kai‐Hang Yiu · 2021 · Cardiovascular Diabetology
98. JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
    Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, Yasuki Kihara, Koichiro Kinugawa, Shintaro Kinugawa, Miyuki Makaya, Toyoaki Murohara, Koichi Node, Yoshihiko Saito et al. · 2021 · Circulation Journal
99. Chronic kidney disease
    Paola Romagnani, Rajiv Agarwal, Juliana C.N. Chan, Adeera Levin, Robert Kalyesubula, Sabine Karam, Masaomi Nangaku, Bernardo Rodríguez‐Iturbe, Hans‐Joachim Anders · 2025 · Nature Reviews Disease Primers
100. TGF-Beta as a Master Regulator of Diabetic Nephropathy
     Li Wang, Honglian Wang, Tong‐Tong Liu · 2021 · International Journal of Molecular Sciences